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Hepatocellular carcinoma (HCC) is a deadly form of liver cancer with high mortality
worldwide. Unfortunately, the large heterogeneity of this disease makes it difficult to
develop effective treatment strategies. Cellular network analyses have been employed
to study heterogeneity in cancer, and to identify potential therapeutic targets.
However, the existing approaches do not consider metabolic growth requirements, i.e.,
biological network functionality, to rank candidate targets while preventing toxicity to
non-cancerous tissues. Here, we developed an algorithm to overcome these issues
based on integration of gene expression data, genome-scale metabolic models, network
controllability, and dispensability, as well as toxicity analysis. This method thus predicts
and ranks potential anticancer non-toxic controlling metabolite and gene targets.
Our algorithm encompasses both objective-driven and—independent tasks, and uses
network topology to finally rank the predicted therapeutic targets. We employed this
algorithm to the analysis of transcriptomic data for 50 HCC patients with both cancerous
and non-cancerous samples. We identified several potential targets that would prevent
cell growth, including 74 anticancer metabolites, and 3 gene targets (PRKACA, PGS1,
and CRLS1). The predicted anticancer metabolites showed good agreement with
existing FDA-approved cancer drugs, and the 3 genes were experimentally validated by
performing experiments in HepG2 and Hep3B liver cancer cell lines. Our observations
indicate that our novel approach successfully identifies therapeutic targets for effective
treatment of cancer. This approach may also be applied to any cancer type that has
tumor and non-tumor gene or protein expression data.
Keywords: hepatocellular carcinoma, genome-scale metabolic model, network analysis, biological networks,
cancer, gene expression, protein expression, systems biology and network biology
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a primary form of liver
cancer and one of the main causes of cancer mortality globally
(Ferlay et al., 2015). Patient prognosis is usually poor and most
result in patient death (Altekruse et al., 2009). This highmortality
is partly due to the high tumor heterogeneity of this cancer
(Friemel et al., 2015; Benfeitas et al., 2017), which makes it
difficult to identify suitable and effective therapeutic targets.
It is therefore urgent to devise suitable approaches capable of
capturing the high tumor heterogeneity for identifying effective
therapeutic targets for this cancer.
Biological network analysis is emerging as an efficient
and suitable in silico approach to identify cellular targets for
disease treatment incorporating cellular heterogeneity (Barabasi
et al., 2011). For instance, network topology features such
as centralized protein hubs have been employed in the
analysis of protein-protein interaction (PPI) networks to identify
potential therapeutic targets (Guney et al., 2016; Lv et al.,
2016). A few efforts have applied network controllability to
identify minimum sets of driver proteins for controlling PPI
networks (Liu et al., 2011; Yuan et al., 2013), or indispensable
proteins from a network controllability perspective (Vinayagam
et al., 2016). Central and highly connected proteins and
genes appear in bottleneck interactions (Wuchty, 2014), and
tend to be essential from a lethality perspective (Jeong
et al., 2001; Yu et al., 2008; Najafi et al., 2014). However,
these approaches have a limited scope in their considered
essentiality analyses and do not take into account comprehensive
descriptions of biological functionality, or the stoichiometry of
the interactions.
Genome-scale metabolic models (GEMs) are whole cell
stoichiometric representations of metabolism that take
into account network functionality through prediction of
a model’s capacity to achieve one or more biological tasks
(e.g., biomolecule synthesis and growth) (Mardinoglu and
Nielsen, 2012, 2015; Mardinoglu et al., 2013). GEMs have
been employed to identify essential genes or anticancer
metabolites, build tissue-specific cellular characterizations,
and explain cell behavior at the metabolic, signaling, gene,
and protein level (Folger et al., 2011; Agren et al., 2014;
Mardinoglu et al., 2014a,b; Varemo et al., 2015). However,
GEM-based methods often do not prioritize between different
candidate therapeutic targets, and assessing toxicity to normal
tissues is not always possible if the essential nodes are not
contemplated by the flux distribution. Further, these approaches
often do not allow for ranking between different candidate
targets.
Here, we overcome the limitations of current state-of-the-art
methods by introducing a network-based prioritization approach
to identify and prioritize non-toxic metabolic targets for disease
treatment using network controllability, topology analysis, and
constraint-based modeling techniques. Our algorithm approach
permits analyzing cellular network behavior using any kind
of expression data such as microarray, transcriptomics (RNA-
seq), or protein expression. Briefly, this algorithm combines
GEMs, personalizedmetabolite-metabolite and reaction-reaction
association networks. Based on the analysis of these networks, it
determines metabolites/genes whose perturbation has a strong
effect on network dynamics (i.e., minimum driver set nodes)
(Yuan et al., 2013), indispensable metabolites/genes (Vinayagam
et al., 2016), and several network topology parameters (i.e.,
node centrality analysis). Based on this information, this
algorithm determines and ranks anticancer metabolites/genes,
excluding those that would also become toxic for non-cancerous
tissues.
We employed this algorithm in the analysis of RNA-seq
data of hepatocellular carcinoma (HCC), the most prevalent
form of liver cancer and third leading cause of cancer-related
mortality worldwide (Ferlay et al., 2010). Through integration of
transcriptomic data from cancerous and non-cancerous samples
and personalized systems biology approaches, we identified
cancer-specific targets. These targets were experimentally
validated in HepG2 and Hep3B cells, cell lines frequently used as
models for liver cancer.
METHODS
Algorithm Overview and Requirements
The algorithm presented here requires Matlab R2016a, RAVEN
and tINIT (Agren et al., 2013, 2014) and has been implemented
on a Dell laptop running Windows 7. It comprises the 4 major
steps detailed below: 1. Objective-dependent identification of
potential targets; 2. Creation of personalized metabolic and
reaction networks; 3. Controllability analysis; and 4. Target
prioritization. We provide an explanation for each of these steps
below, as well as pseudo-code or original references showing their
implementation.
Step 1. Objective-Dependent Identification
of Potential Targets
We identify metabolites and genes that potentially serve as
therapeutic targets based on antimetabolites and in silico gene
silencing of personalized GEMs. The two approaches rely on
objective function and metabolic tasks for cancer and non-
cancerous tissues to determine the functional outcome, i.e., viable
vs. non-viable. Viability is determined for instance by testing
whether objective-functions are non-null. Importantly, toxicity
testing is done by identifying those antimetabolites/silenced
genes that render tumors non-viable, but maintain viability in
non-cancerous cells.
Step 1a. Antimetabolites are those structurally similar to
endogenous metabolites and that prevent cell growth. Basically,
for each metabolite and regardless of compartmentalization, an
antimetabolite is identified by removing the reactions where the
metabolite serves as substrate. This step was implemented using
tINIT as previously indicated (Agren et al., 2014).
Step 1b. The concept of in silico gene silencing is similar to
lethality analyses but considers metabolic tasks (Supplementary
File 1) in addition to objective functions to assess model
functionality, to assess the effect of gene silencing. In order to
simulate the effect of gene silencing for each gene on the models,
we removed the reaction(s) catalyzed by the gene.
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Algorithm STEP 1b: In silico gene silencing
INPUT greferenceGEM ,
INPUT CancerTask file
INPUT NoncancerTask file
q=number of personalized model
FOR h= 1 to q
model=GEMh
FOR i=1 to length(g)
IF ismember (greferenceGEM, g) ANDmodel is cancerous
THEN
reducedModel= removeGenes (model, gi)
taskReport=checkTasks (reducedModel, Cancertask)
% tINIT function to check metabolic tasks, i.e., model
viability
IF NOT all(taskReport.ok)
Cancer_matrix(i, h)=1
ENDIF
ELSEIF ismember (greferenceGEM, g) THEN
reducedModel=removeGenes(model, gi)
taskReport=checkTasks (reducedModel,
Noncancertask)
% tINIT function to check metabolic tasks, i.e., model
viability
IF NOT all (taskReport.ok)
Noncancer_matrix (i, h)=1
ENDIF
ENDIF
ENDFOR
ENDFOR
Step 1c. The predicted antimetabolites (Step 1a) and silenced
genes (Step 1b) are filtered to select only those found in HCC
GEMs but not in non-cancerous GEMs.
Step 2. Creation of Personalized Metabolic
and Reaction Networks
Personalized GEMs are used to generate directed Metabolite-
Metabolite network (MMN, Step 2a), and directed Reaction-
Reaction network (RRN, Step 2b). MMN and RRN are simple
graphs G(V, E) with V nodes and E edges. In MMN, nodes
(metabolites) are connected by an edge if they are involved in
the same reaction. In RRN, nodes (reactions) are connected
if the product of a reaction serves as substrate by the other
(Supplementary Figure 1).
Step 3. Controllability Analysis
We identify minimum driver set nodes (MDS), those responsible
for controlling network dynamics upon perturbation (Yuan et al.,
2013), as well as indispensable nodes (Vinayagam et al., 2016),
fromMMN (Step 2a) and RRN (Step 2b). MDS and indispensable
nodes (metabolites or genes) are jointly used for subsequent
steps, and termed controlling nodes.
Step 3a. We identify MDS in MMN and RRN according to the
Popov–Belevitch–Hautus (PBH) rank condition (Sontag, 2013;
Yuan et al., 2013).
Algorithm STEP 2a: Creation of directed metabolite-
metabolite networks
INPUT personalized GEM
REMOVE xcurr from GEM
m= number of rows of S
n= number of columns of S
FOR h=1 to n
ind=find(S(:,h))
w= number of rows of ind; d=1
WHILE d < w
IF S(ind(d),h)<0 AND S(ind(d+1),h)>0 THEN
IF rev(h)==1 THEN % tINIT function, identifies the
set of reversible reactions
PRINT xind(d)→ xind(d+1), xind(d+1)→ xind(d)
ELSE
PRINT xind(d)→ xind(d+1)
ENDIF
ELSEIF S(ind(d),h)>0 AND S(ind(d+1),h)<0 THEN
IF rev(h)==1 THEN % tINIT function, identifies the
set of reversible reactions
PRINT xind(d+1)→ xind(d), xind(d)→ xind(d+1)
ELSE
PRINT xind(d+1)→ xind(d)
ENDIF
ENDIF
d=d+1
ENDWHILE
ENDFOR
Step 3b. Node dispensability is determined by assessing the
maximum geometric multiplicity of the eigenvalue λm upon
removing each node.
Step 3c. We excluded those nodes that were simultaneously
identified in both HCC and non-cancerous networks in Steps 3a
and 3b.
Step 4. Target Prioritization
In the final step, we filter nodes by selecting those with
anticancer properties (Step 1, metabolic task dependent) that
are also controlling metabolites/genes (Step 3, metabolic task
independent). This generates a list of anticancer non-toxic
controlling nodes that are then ranked based on their centrality
properties.
Step 4a. Filter nodes simultaneously identified as controlling
nodes (Step 3) with anticancer properties (Step 1).
Step 4b. We compute topological parameters for MMN and
RRN. Specifically, we compute node degree and betweenness
centrality using default commands [e.g., Matlab R2016a built-in
degree() and centrality() functions].
Step 4c. Based on each node’s topological measures, we
rank anticancer controlling nodes. Indispensable nodes are
ranked based on degree centrality whereas MDS are ranked
based on betweenness centrality. This results in a list of nodes
(metabolites/genes) with anticancer and controlling properties,
sorted according to their topological importance in the networks.
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Algorithm STEP 2b: Creation of directed reaction-reaction
networks
FOR h=1 tom
in=find(S(h,:))
κ =number of columns of in; v=1
WHILE v< κ
IF S(h,in(v))<0 AND S(h,in(v+1))>0 THEN
IF rev(in(v))==1 AND rev(in(v+1))==1 THEN
PRINT rin(v)→ rin(v+1), rin(v+1)→ rin (v)
ELSE
PRINT rin(w)→ rin(W+1)
ENDIF
ELSEIF S(h,in(v))>0 AND S(h,in(v+1))<0 THEN
IF rev(in(v))==1 AND rev(in(v+1))==1 THEN
PRINT rin(v+1)→ rin(v), rin(v)→ rin(v+1)
ELSE
PRINT rin(v+1)→ rin(v)
ENDIF
ENDIF
v=v+1
ENDWHILE
ENDFOR
Gene Expression Data and Modeling for
HCC Patients
Transcriptomic data (RNA-seq) for 50HCC and 50 adjacent non-
cancerous liver samples were retrieved from NCI’s Genome Data
Commons (Grossman et al., 2016) as Fragments Per Kilobase
of transcript per Million mapped reads (FPKM). Personalized
GEMs were built by integrating transcriptomic data with the
liver-specific GEMs through tINIT and RAVEN (Agren et al.,
2013, 2014) using the reference humanGEMHMR2 (Uhlen et al.,
2017).
The following thresholds for gene levels were considered:
no expression (FPKM<1), low expression (1≤FPKM<10),
medium expression (10≤FPKM<50), and high (FPKM≥50). We
considered biomass production or ATP consumption as objective
functions for HCC and non-cancer GEMs, respectively. Model
functionality of HCC and non-cancer GEMs was respectively
determined based on 57 and 56 metabolic tasks, as previously
determined (Agren et al., 2014). Cell growth is considered as an
additional metabolic task for HCC.
HepG2 and Hep3B Cell Line Experiments
HepG2 and Hep3B, human hepatocellular carcinoma cell lines
frequently used as models for liver cancer (Qiu et al., 2015),
were cultured in RPMI-1640 Medium (R2405, Sigma-Aldrich)
and Minimum Essential Medium Eagle (M4655, Sigma-Aldrich),
respectively. Both cell lines were supplemented with 10% fetal
bovine serum (FBS, F2442, Sigma-Aldrich) and incubated in
5% CO2 humidity at 37
◦C. To confirm the effect of silencing
of CRLS1, PRKACA and PGS1 genes on cancer cell growth
and viability, we used RNA interference (RNAi) to inhibit
gene expression. Cells were infected by predesigned targeted
Silencer R© siRNAs for each gene (Thermo Fisher Scientific,
Algorithm STEP 3b: Determination of node dispensaiblity
INPUT graph: MMN or RRN
G=transpose (graph)
v= number of V
λ= eigenvalue(G)
λm=maximum geometric multiplicity of λ
nMDS= v – rank (λm× eigenvalue(v) - G)
FOR h 1 to v
Gr= removenode(graph,Vv)
v1= number of Gr nodes
Gr =transpose(Gr)
λ1= eigenvalue(Gr)
λm1=maximum geometric multiplicity of λ
nMDS1= v1 – rank (λm1× eigenvalue(v1) - Gr)
IF nMDS1> nMDS THEN
PRINT Vv is “indispensable”
ELSEIF nMDS1< nMDS THEN
PRINT Vv is “dispensable”
ELSE
PRINT Vv is “neutral”
ENDIF
ENDFOR
clone IDs shown in Supplementary File 2), at 35 nM by using
Lipofectamine R© RNAiMAX (13778075, Life Technologies). Cells
incubated in medium with non-targeting negative control
siRNA at 35 nM (4390843, Life Technologies) were assigned as
control.
Total RNA was isolated with RNeasy mini Kit (15596026,
Thermo Fisher Scientific) after treatment with siRNA for 24 h.
The expression profiles of key genes (CRLS1, PRKACA and
PGS1) in HepG2 and Hep3B cells separately were measured
and analyzed via quantitative real-time PCR with iTaq Universal
SYBR Green One-Step Kit (1725151, Bio-Rad), using anchored
oligo (dT) primer based on CFX96TM detection system (Bio-Rad).
GAPDHwas set as the internal control for normalization. Primer
sequences are listed in Supplementary File 2. Cell Counting Kit-
8 (CCK-8, Sigma-Aldrich) was used to detect variation in cell
proliferation after interference by siRNA for 24 h.
All experiments were performed strictly according to the
manufacturer’s instructions and repeated in triplicate.
Statistics
Statistic comparison between siRNA-targeted gene expression
and non-negative controls was performed using Welch’s t-test,
corrected for Benjamini & Hochberg.
RESULTS
Algorithm
GEMs include metabolites (x), reversible and irreversible
reactions (r), and associated genes (g). Reactions are represented
as a stoichiometric matrix (S) of size m×n, where rows (m)
in S represent metabolites and columns (n) correspond to
reactions in the model (Supplementary Figure 1). Each entry is
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a stoichiometric coefficient sij of the metabolites that participate
in a reaction. sij ≥ 1 and sij ≤ −1 respectively indicate that
metabolite i is a product or reactant in reaction j, whereas
sij = 0 indicates no involvement in the reaction. Reaction
reversibility is discriminated by the rev vector, where 0 and
1 respectively indicate an irreversible or reversible reaction.
Currency metabolites (xcurr) such as cofactors, coenzymes and
H2O are found in a number of reactions and considered by the
GEMs, but are disregarded when creating metabolite-metabolite
and reaction-reaction association networks(Khosraviani et al.,
2016).
Our algorithm (Figure 1, Supplementary Figure 2) predicts
potential metabolite and gene targets that display anticancer
activity but are non-toxic to non-cancerous tissues. To do
so, it integrates expression data (transcriptomics, microarray
or protein levels) into GEMs (Methods, Algorithm steps
1b–2b) to generate cancer and non-cancer specific models.
After network manipulation and analysis, it identifies and
prioritizes anticancer metabolites and gene targets (Algorithm
step 3b). These were implemented in Matlab, and require
RAVEN and tINIT (Agren et al., 2013, 2014). Our hypothesis
follows the determination of metabolite or genes that display
anticancer and network-controlling properties, and sorting
them according to their topology parameters. The highest
ranking (most central) nodes are potentially better targets
due to their pivotal and central role in network dynamics,
and are excluded if identified in non-cancerous tissues to
prevent toxicity. Several filtering steps are taken to exclude
false positives: candidate anticancer targets must have network
controlling properties and cannot be found in non-cancerous
networks, i.e., they must be anticancer non-toxic controlling
nodes.
This algorithm consists of 4 main steps, applied to both cancer
and non-cancer personalized GEMs (details in section Methods),
constructed using expression data and reference models (Uhlen
et al., 2017). Step 1 is independent of steps 2 and 3, and all are
integrated at Step 4.
(1) Objective-dependent identification of potential targets
a. Antimetabolite analysis
b. In silico gene silencing
c. Toxicity analysis
(2) Creation of personalized metabolite and reaction networks
a. Creating metabolite-metabolite networks
b. Creating reaction-reaction networks
(3) Controllability analysis
a. Identification of Minimum Driver Set Nodes
b. Dispensability analysis
c. Toxicity analysis
(4) Target prioritization
a. Determining anticancer non-toxic controlling nodes
b. Computation of centrality parameters
c. Target prioritization
FIGURE 1 | Outline of network-based identification and prioritization of
metabolite and gene anticancer targets.
All steps are described in detail according to a toy model
(Supplementary Figures 1, 2) and pseudo-code is described in
section Methods.
Determination of Antimetabolites,
Anticancer Genes, and Networks Based on
Personalized GEMs in HCC
As a test case, we sought to identify non-toxic cancer targets using
50 HCC and 50 non-cancerous transcriptomic samples from
TCGA. This test case employs liver-specific GEMs (Uhlen et al.,
2017), which encompass 7,780 reactions and 2,857 metabolites
controlled by 2,892 genes. We built functional personalized
GEMs for HCC and non-cancerous samples (Supplementary
File 3) where model functionality was determined based on the
metabolic tasks and the objective functions.
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We then identified 374 antimetabolites out of 2,857
metabolites that inhibited growth of HCC GEMs, but passed all
metabolic tasks in non-cancerous GEMs, i.e., non-toxic cancer-
specific antimetabolites (Steps 1a and 1c, Supplementary File 4).
Most antimetabolites are involved in carnitine shuttle, fatty acid
activation, and acyl-CoA hydrolysis, as well as metabolism of
cholesterol, glycerolipid, glycan, purine, pyrimidine, nucleotide,
amino acid, and proteins (Figure 2A).
Based on in silico gene silencing, we found that 2,204 genes
did not fulfill all 56 metabolic tasks in non-cancerous models.
We identified 283 genes that inhibited the growth in at least
one HCC, and 8 genes that inhibit growth in all HCC models,
but induced no change in non-cancer GEMs (Steps 1b and 1c,
Figure 2D, Supplementary File 4).
We also generated MMN and RRN for each personalized
GEM (Steps 2a and 2b, respectively). The generated MMN
and RRN showed scale free (power-law) degree distribution,
and the cumulative degree distribution of the networks were
compared with random networks generated by Erdos–Rényi
model (Figure 2B).
Identification of Non-toxic Anticancer
Controlling Metabolites Using
Metabolite-Metabolite Network
Controllability
We identified cancer-exclusive controlling metabolites in all
GEMs (Step 3, Supplementary File 4). Specifically, we found 201
MDS metabolites, most of which are involved in exchange and
transporting reactions. Most amino acids, (deoxy)nucleotides,
fatty acids and cholesterol, and some sugars including mannose,
glucose, fructose, and galactose, are MDS in HCC models. In
turn, we identify 578 indispensable metabolites, most of which
either start metabolic pathways or are important metabolites
in the networks, such as malonyl-CoA, palmitoyl-CoA, glucose,
mannose, glucose-6-phosphate, HMG-CoA, (deoxy)nucleotides,
DNA, acetyl-CoA, amino acids, L-carnitine, fatty acids, and
coenzymes. Indispensable metabolites present higher degree in
MMN (Supplementary File 4), in comparison with other node
types in both non-cancer and cancer networks (Figure 2C).
Because of this, the indispensable nodes are ranked based on
node degree parameters (Step 4c). After removing metabolites
simultaneously found in HCC and non-cancerous networks, we
identify 142 cancer-specific controlling metabolites which were
used in the subsequent steps (Supplementary File 4). The 374
antimetabolites found in Steps 1a and 1c were filtered based on
the 142 cancer-specific controlling metabolites. This results in
74 non-toxic anticancer metabolites with network controlling
properties, potential targets for antimetabolite treatment (Step
4a). Among the 74 anticancer controlling metabolites, 54
are indispensable and 20 are MDS (Supplementary File 4).
The anticancer indispensable controlling metabolites shows
substantially higher degree (Supplementary File 4). For instance,
the top ranking indispensable antimetabolites show high degree
(leucine 79, isoleucine 78, UMP 66, malonyl-CoA 34, palmitoyl-
CoA 16) when compared with mean metabolite degree = 6.
The 75 anticancer controlling metabolites are mostly involved
in metabolism of DNA and nucleotides, amino acids, and fatty
acids.
Importantly, while several nodes present very high centrality,
they may not be suitable therapeutic targets because their
silencing either does not lead to lethality, or leads to
lethality in both cancer and non-cancer networks (i.e., toxicity,
Supplementary Files 4, 5).
Overall, our network-based approaches highlight several
potential metabolic targets for cancer-specific treatment.
Identification of Gene Targets Exclusive to
HCC Using Reaction-Reaction Network
and Experimental Validation
Silencing of controlling genes in RRN shows specific features
in HCC and non-cancerous networks (Figure 3). Among the
eight genes that inhibit growth in all HCC but not in non-
cancerous models, we identify three genes that are controlling
nodes in HCC RRN but not in non-cancerous RRN (Step 3,
Supplementary File 5): PRKACA (protein kinase cAMP-activated
catalytic subunit alpha), PGS1 (phosphatidylglycerophosphate
synthase 1), CRLS1 (cardiolipin synthase 1). Since they are
indispensable nodes, we then ranked them based on degree
parameter as PRKACA, PGS1, and CRLS1 (Supplementary File
5), from most to least central genes.
We tested the anticancer properties of these three genes
using siRNA in HepG2 and Hep3B cells (Figure 4). Cell viability
was tested 24 h after gene silencing using the CCK-8 assay
(see Methods). As negative controls, cells were exposed to a
non-targeting siRNA. Our observations indicate that PRKACA
silencing led to 22–24% decrease in cell growth in both cell lines
(P < 0.05). CRLS1 silencing led to 30% lower growth in HepG2
(P < 0.05) but no change in Hep3B. Finally, PGS1 silencing
produced the most substantial growth change, decreasing growth
in Hep3B by 35% (Q< 0.05).
DISCUSSION
Network analyses have been extensively used in understanding
cellular response to disease and predicting targets for treatment.
Due to their comprehensive and integrative nature, networks
successfully and efficiently capture multidimensional biological
heterogeneity (Mardinoglu and Nielsen, 2012, 2015; Mardinoglu
et al., 2013; Najafi et al., 2014; Benfeitas et al., 2017). Such
cases include topology (Asgari et al., 2013), controllability (Liu
et al., 2011; Yuan et al., 2013; Wuchty, 2014; Kanhaiya et al.,
2017), dispensability (Vinayagam et al., 2016), and genome-
scale metabolic models (Mardinoglu and Nielsen, 2012, 2015;
Mardinoglu et al., 2013; Agren et al., 2014) in prediction of
disease targets. For instance, a recent analysis shows that a
small number of proteins essential for survival are controlled
by a small set of driver nodes (Kanhaiya et al., 2017).
Network controllability analyses have also highlighted that highly
connected proteins are critical for cell survival (Jeong et al., 2001;
Jonsson and Bates, 2006). In turn, others have used metabolic
networks to identify candidate metabolite analogs and genes
with anticancer properties (Agren et al., 2014). While these
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FIGURE 2 | General MMN and RRN node features in HCC. (A) Number of antimetabolites identified per pathway. Note that a predicted antimetabolite may be found
in multiple pathways. (B) Cumulative degree distribution for MMN (purple) and RRN (magenta), compared to randomly generated models (Erdos–Rényi, dots). RRNs
show qualitatively similar properties (results not shown). (C) Mean degree for indispensable, neutral, and dispensable metabolites in noncancer and HCC MMNs.
RRNs show qualitatively similar properties (results not shown). (D) Number of genes leading to lethality identified per pathway. Note that a predicted synthetic lethal
gene may be found in multiple pathways.
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FIGURE 3 | Pivotal genes in HCC (Left) and non-cancerous (Right) RRN. Node size is proportional to degree centrality, and controlling anticancer genes are
highlighted (red means higher number of patients where gene silencing leads to lethality and where a gene is a controlling node).
efforts have undoubtedly provided great contributions to clarify
the underlying disease biological phenomena, and identified
pivotal components for controlling network dynamics, such
methods have specific shortcomings. For instance, topology-
based approaches often do not take into account interaction
stoichiometry, and essentiality analyses do not consider multiple
functionality properties necessary for growth, e.g., energetic and
redox balance, maintenance of central metabolism (see Agren
et al., 2014 and references therein).
Here, we developed an algorithm that integrates expression
data with both objective-dependent and objective-independent
approaches to identify and rank metabolites and genes for
cancer treatment. Objective dependent approaches such as flux
balance analysis, employed here, base their predictions on
satisfying specific biological phenomena. However, our method
overcomes some of the disadvantages in FBA-based approaches
which, unlike our method, do not permit ranking multiple
candidate targets, and assessing potential toxic targets is not
always possible if the essential nodes are not contemplated
by the flux distribution. Objective independent approaches,
including network topology, controllability, and dispensability
analysis employed here, permit classifying and ranking between
nodes. In our algorithms, candidate targets are filtered at
multiple steps based on their toxicity, network controllability
and anticancer properties. Thus, and unlike typical network
topology analysis, our proposed method incorporates biological
functionality expressed as metabolic requirements, and reaction
stoichiometry. To our knowledge, this is the first such case where
prioritization and classification of potential metabolite/gene
targets is determined while considering toxicity to non-cancerous
tissues and biological functionality.
We employed this algorithm for the analysis of hepatocellular
carcinoma, a deadly form of liver cancer (Ferlay et al., 2010).
This transcriptomic dataset comprised 50 tumor and 50 non-
cancerous samples, retrieved form TCGA (Weinstein et al.,
2013). We identify 142 metabolites, and 3 genes as potential
therapeutic targets for non-toxic treatment of this liver cancer.
The non-toxic anticancer metabolites identified in here tend
to be involved in metabolism of DNA and nucleotides, amino
acids, and fatty acids. Several observations support utilization
of analogs of these metabolites or targeting these biological
processes for cancer treatment. For instance, several pyrimidine
or purine analogs are among FDA-approved drugs for cancer
therapy in DrugBank (Law et al., 2014), such as Gemcitabine,
Fluorouracil, Clofarabine, Azacitidine, Floxuridine, Cladribine,
Raltitrexed, Tioguanine, Azacitidine. All amino acids analogs
were found as antimetabolites but most of them were filtered
based on cancer controlling metabolites as toxic targets based
on controllability analysis. Among all amino acids, glutamine,
leucine, and isoleucine were introduced as nontoxic anticancer
metabolite targets. Several studies show the critical role of amino
acids such as glutamine in cancer (Xie et al., 2012; Bhutia
et al., 2015; Xiao et al., 2016; Fung and Chan, 2017; Maddocks
et al., 2017). For instance, leucine and isoleucine supplementation
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FIGURE 4 | siRNA inhibition of CRLS1, PGS1, and PRKACA expression in
Hep3B and HepG2 liver cell lines leads to decreased growth after 24 h in
comparison with controls. Comparisons performed using Welch’s T-test. See
methods for details.
promote tumorigenesis in rat bladder cancer (Xie et al., 2012),
and leucine deprivation inhibits breast cancer proliferation in
humans (Xiao et al., 2016).
Other metabolites such as fatty acids also display a crucial role
in cancer. For instance, malonyl-CoA serves as substrate for fatty
acid synthase, and inhibition of this enzyme with the synthetic
inhibitor C75 (Kuhajda et al., 2000) significantly decreases
growth in HepG2 cells (Gao et al., 2006). Our previous work
identified L-carnitine and metabolites involved in L-carnitine
biosynthesis as non-toxic anticancer HCC targets using protein
levels for 6 HCC samples (Agren et al., 2014). Our algorithm
presented here improves on this work by showing that L-
carnitine is a non-toxic anticancer target for HCC treatment
(Step 2, Supplementary File 3) using a different technology
and sample, and network topology analyses indicate that other
metabolites may have better network controlling properties than
L-carnitine.
At the gene level, only 3 genes pass all the filtering criteria,
and show anticancer non-toxic controlling properties: protein
kinase cAMP-activated catalytic subunit alpha (PRKACA),
phosphatidylglycerophosphate synthase 1 (PGS1), and
cardiolipin synthase 1 (CRLS1). We experimentally confirmed
that the 3 genes display anticancer properties using siRNA
in HepG2 and Hep3B liver cancer cell lines. We observe that
depletion of PGS1 and PRKACA greatly decreases growth in
both HepG2 and Hep3B, whereas depletion of CRLS1 decreases
expression in HepG2. These genes have been associated with
alterations in proliferation, malignancy and apoptosis in several
cancers. The cAMP-dependent protein kinase A has crucial
signaling roles in cancer, promotes resistance to therapy and
its inhibition blocks tumor invasion (Sabbisetti et al., 2005;
Honeyman et al., 2014; Moody et al., 2015). PGS1 metabolizes
phosphatidylglycerol in lipid metabolism, is involved in cellular
transformation, and its upregulated in metastases (Hirsch et al.,
2010; Hartung et al., 2017). Finally, cardiolipin synthase 1 is
involved in phosphatidylglycerol metabolism, and alterations in
cardiolipin metabolism are associated with proliferation and cell
death (Schug and Gottlieb, 2009; Sapandowski et al., 2015).
Overall, these observations indicate that our algorithm
successfully identifies several metabolites and genes that may be
targeted for cancer treatment. The observations in both MMNs
and RRNs show the necessity for combining both topology-
and objective-dependent analyses in identification of suitable
therapeutic targets. These approaches may be employed together
with other omics technologies, to identify and develop targeted
therapeutic strategies in other cancers.
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